Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Biogen Inc Cmn (BIIB) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 62,869,524
  • Shares Outstanding, K 215,950
  • Annual Sales, $ 11,449 M
  • Annual Income, $ 3,703 M
  • 36-Month Beta 0.72
  • Price/Sales 5.38
  • Price/Cash Flow 12.06
  • Price/Book 5.08

Price Performance

See More
Period Period Low Period High Performance
1-Month
250.45 +16.24%
on 01/31/17
293.98 -0.97%
on 02/16/17
+34.87 (+13.61%)
since 01/27/17
3-Month
250.02 +16.44%
on 01/25/17
293.98 -0.97%
on 02/16/17
+10.01 (+3.56%)
since 11/25/16
52-Week
205.43 +41.72%
on 06/27/16
307.33 -5.27%
on 08/02/16
+47.51 (+19.50%)
since 02/26/16

Most Recent Stories

More News
Ionis (IONS) Q4 Earnings: What's in the Cards for the Stock?

Ionis Pharmaceuticals, Inc. (IONS) is scheduled to report fourth-quarter 2016 results on Feb 28.

EXAS : 22.17 (+3.50%)
IONS : 46.90 (+5.18%)
EXEL : 23.09 (+6.45%)
BIIB : 291.13 (+2.10%)
Alzheimer's Market Suffers Yet Another Blow with Merck Drug Setback

Merck's (MRK) news represents the latest setback in the pharma and biotech sector's quest to find a treatment for Alzheimer's.

AZN : 29.37 (+0.07%)
JNJ : 122.40 (-0.27%)
MRK : 65.85 (-0.47%)
LLY : 83.06 (+0.23%)
NVS : 77.58 (+0.39%)
AMGN : 176.13 (+0.90%)
BIIB : 291.13 (+2.10%)
Biogen to Present at the 2017 RBC Capital Markets Global Healthcare Conference

Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the 2017 RBC Capital Markets Global Healthcare Conference. The webcast will be live on Wednesday, February 22, 2017...

BIIB : 291.13 (+2.10%)
This Chart Reveals a Hidden Bull Market

This post This Chart Reveals a Hidden Bull Market appeared first on Daily Reckoning . There’s nothing quite like an earnings-driven comeback. Especially when you’re dealing with a speculative...

CELG : 121.78 (+3.00%)
XLV : 75.14 (+0.48%)
AMGN : 176.13 (+0.90%)
XBI : 70.48 (+4.82%)
BIIB : 291.13 (+2.10%)
Biotech Stock Roundup: Regeneron's Praluent to Remain on Market for Now, GILD Presents HIV Data

Gilead (GILD) presented promising HIV data while Regeneron's PCSK9 inhibitor will remain on the market during the appeals process.

CELG : 121.78 (+3.00%)
INCY : 134.02 (+2.14%)
GILD : 70.50 (+0.80%)
ACOR : 27.40 (+10.04%)
SGEN : 65.92 (+5.09%)
REGN : 373.05 (+3.34%)
BIIB : 291.13 (+2.10%)
Drug Stocks Earnings Slated for Feb 14: INCY, PRTA & More

The year 2017 seems to have started on a positive note for investors in the U.S. Approximately 71.6% of the companies (or 358 members) in the S&P 500 Index have reported results so far.

CELG : 121.78 (+3.00%)
JNJ : 122.40 (-0.27%)
LLY : 83.06 (+0.23%)
AXON : 12.61 (+7.59%)
INCY : 134.02 (+2.14%)
PRTA : 58.01 (+8.53%)
GILD : 70.50 (+0.80%)
ACOR : 27.40 (+10.04%)
ABBV : 62.22 (+0.21%)
PFE : 34.28 (+0.06%)
BIIB : 291.13 (+2.10%)
Biotech ETFs Powered by Q4 Earnings

Improved earnings are driving the biotech space and ETFs higher over the past 10 days.

CELG : 121.78 (+3.00%)
ILMN : 166.82 (+4.26%)
IBB : 298.27 (+2.89%)
VRTX : 88.90 (+3.29%)
FBT : 103.72 (+3.76%)
BBH : 121.33 (+2.39%)
GILD : 70.50 (+0.80%)
AMGN : 176.13 (+0.90%)
BIIB : 291.13 (+2.10%)
Biotech ETFs Powered by Q4 Earnings

Improved earnings are driving the biotech space and ETFs higher over the past 10 days.

CELG : 121.78 (+3.00%)
ILMN : 166.82 (+4.26%)
IBB : 298.27 (+2.89%)
VRTX : 88.90 (+3.29%)
FBT : 103.72 (+3.76%)
BBH : 121.33 (+2.39%)
GILD : 70.50 (+0.80%)
AMGN : 176.13 (+0.90%)
BIIB : 291.13 (+2.10%)
Biotech Stock Roundup: Amgen, Gilead Report 4Q Results, ARIAD Seeks EU Nod for Brigatinib

Although both Amgen (AMGN) and Gilead reported better-than-expected 4Q results, the companies provided a disappointing sales outlook for 2017.

STML : 7.05 (+2.92%)
ARIA : 23.99 (+0.17%)
GWPH : 125.41 (+1.35%)
GILD : 70.50 (+0.80%)
REGN : 373.05 (+3.34%)
AMGN : 176.13 (+0.90%)
BIIB : 291.13 (+2.10%)
Biogen to Present at the Leerink Partners 6th Annual Global Healthcare Conference

Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the Leerink Partners 6th Annual Global Healthcare Conference. The webcast will be live on Wednesday, February 15,...

BIIB : 291.13 (+2.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

See More

Business Summary

Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia,...

See More

Support & Resistance

2nd Resistance Point 295.86
1st Resistance Point 293.50
Last Price 291.13
1st Support Level 286.52
2nd Support Level 281.90

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.